X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4) 4
oncology (4) 4
aged (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cancer (3) 3
female (3) 3
hematology, oncology and palliative medicine (3) 3
humans (3) 3
male (3) 3
middle aged (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
cancer therapies (2) 2
capecitabine (2) 2
chemoradiation (2) 2
chemoradiotherapy (2) 2
chemotherapy, adjuvant (2) 2
clinical trials (2) 2
colorectal cancer (2) 2
fluorouracil - administration & dosage (2) 2
fluorouracil - therapeutic use (2) 2
germany (2) 2
iii trial (2) 2
leucovorin (2) 2
medical informatics (2) 2
mrc cr07 (2) 2
oncology, experimental (2) 2
organoplatinum compounds - administration & dosage (2) 2
oxaliplatin (2) 2
radiotherapy (2) 2
rectal neoplasms - therapy (2) 2
research (2) 2
surgery (2) 2
time factors (2) 2
treatment outcome (2) 2
1st-line treatment (1) 1
5-fluorouracil (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - secondary (1) 1
adenocarcinoma - therapy (1) 1
adjuvant chemotherapy (1) 1
adjuvant treatment (1) 1
adult (1) 1
aged, 80 and over (1) 1
akt protein (1) 1
amplification (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibodies, monoclonal, humanized (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
austria (1) 1
bevacizumab (1) 1
biometry (1) 1
breast cancer (1) 1
camptothecin - adverse effects (1) 1
camptothecin - analogs & derivatives (1) 1
camptothecin - therapeutic use (1) 1
carcinoma (1) 1
cell lines (1) 1
cetuximab (1) 1
chemoradiotherapy, adjuvant - adverse effects (1) 1
chemoradiotherapy, adjuvant - mortality (1) 1
chemotherapy (1) 1
colon-cancer (1) 1
colorectal carcinoma (1) 1
colorectal neoplasms - pathology (1) 1
consent (1) 1
copy number (1) 1
disease progression (1) 1
disease-free survival (1) 1
dose fractionation (1) 1
drug administration schedule (1) 1
drug dosages (1) 1
epidermal growth factor (1) 1
erbb protein (1) 1
erbb-2 protein (1) 1
experiments (1) 1
expression (1) 1
fees & charges (1) 1
fluorouracil (1) 1
fluorouracil - adverse effects (1) 1
follow-up (1) 1
further section (1) 1
gastric-cancer (1) 1
hepatectomy (1) 1
hepatic resection (1) 1
her-2 (1) 1
her-3 (1) 1
infusions, intravenous (1) 1
inhibitors (1) 1
intention to treat analysis (1) 1
kaplan-meier estimate (1) 1
kinases (1) 1
leucovorin - adverse effects (1) 1
leucovorin - therapeutic use (1) 1
linear models (1) 1
liver (1) 1
liver metastases (1) 1
liver neoplasms - chemistry (1) 1
liver neoplasms - drug therapy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 979 - 989
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 7, pp. 679 - 687
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 38 - 47
Summary Background Neoadjuvant chemotherapy for unresectable colorectal liver metastases can downsize tumours for curative resection. We assessed the... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | BEVACIZUMAB | OXALIPLATIN | FLUOROURACIL | HEPATIC RESECTION | CANCER | CARCINOMA | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Tomography, Spiral Computed | Liver Neoplasms - chemistry | Hepatectomy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Austria | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Female | Leucovorin - therapeutic use | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Cetuximab | Liver Neoplasms - secondary | Odds Ratio | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Liver Neoplasms - genetics | Risk Assessment | Liver Neoplasms - drug therapy | Linear Models | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Germany | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
BMC CANCER, ISSN 1471-2407, 09/2019, Volume 19, Issue 1, pp. 880 - 12
Background Abrogation of growth factor-dependent signaling represents an effective therapeutic strategy for patients with colorectal cancer (CRC). Here we... 
Targeted therapy | Colorectal cancer | VALIDATION | CHEMORADIOTHERAPY | MECHANISMS | HER-3 | HER-2 | LIVER METASTASES | RECTAL-CANCER | Inhibitors | AMPLIFICATION | ONCOLOGY | GASTRIC-CANCER | COPY NUMBER | EXPRESSION | STANDARD
Journal Article
Oncology Research and Treatment, ISSN 2296-5270, 05/2011, Volume 34, Issue 3, pp. 32 - 32
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.